NASDAQ:SLDB - Solid Biosciences Stock Price, News & Analysis

$8.81
+2.66 (+43.25 %)
(As of 08/19/2019 02:19 AM ET)
Today's Range
$6.74
Now: $8.81
$8.99
50-Day Range
$4.35
MA: $5.52
$8.27
52-Week Range
$4.32
Now: $8.81
$54.54
Volume2.83 million shs
Average Volume632,402 shs
Market Capitalization$311.96 million
P/E RatioN/A
Dividend YieldN/A
Beta2.07
Solid Biosciences Inc, a life science company, engages in identifying and developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, an adeno-associated viral vector-mediated gene transfer, which is in a Phase I/II clinical trial to restore functional dystrophin protein expression in patients' muscles. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SLDB
CUSIPN/A
Phone617-337-4680

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.16 per share

Profitability

Net Income$-74,800,000.00

Miscellaneous

Employees111
Market Cap$311.96 million
Next Earnings Date11/12/2019 (Estimated)
OptionableOptionable

Receive SLDB News and Ratings via Email

Sign-up to receive the latest news and ratings for SLDB and its competitors with MarketBeat's FREE daily newsletter.


Solid Biosciences (NASDAQ:SLDB) Frequently Asked Questions

What is Solid Biosciences' stock symbol?

Solid Biosciences trades on the NASDAQ under the ticker symbol "SLDB."

How were Solid Biosciences' earnings last quarter?

Solid Biosciences Inc (NASDAQ:SLDB) released its quarterly earnings results on Wednesday, August, 14th. The company reported ($0.76) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.81) by $0.05. View Solid Biosciences' Earnings History.

When is Solid Biosciences' next earnings date?

Solid Biosciences is scheduled to release their next quarterly earnings announcement on Tuesday, November 12th 2019. View Earnings Estimates for Solid Biosciences.

What price target have analysts set for SLDB?

7 brokers have issued 1-year price objectives for Solid Biosciences' stock. Their predictions range from $4.00 to $10.00. On average, they anticipate Solid Biosciences' share price to reach $6.50 in the next twelve months. This suggests that the stock has a possible downside of 26.2%. View Analyst Price Targets for Solid Biosciences.

What is the consensus analysts' recommendation for Solid Biosciences?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Solid Biosciences in the last year. There are currently 2 sell ratings, 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Solid Biosciences.

What are Wall Street analysts saying about Solid Biosciences stock?

Here are some recent quotes from research analysts about Solid Biosciences stock:
  • 1. Chardan Capital analysts commented, "We thus now upgrade SLDB from Neutral to Buy, increasing our PT from $7.50 to $10, ahead of Solid’s anticipated IGNITE DMD data update later this year. The risks surrounding SGT-001 are well-known to the market, and any improvements in the market’s view of SGT-001 safety and/or efficacy (e.g. with the IGNITE DMD data update later this year) could lead to significant share price momentum. Recall, Solid has reported adverse events in prior patients dosed with SGT-001. Solid announced the FDA placed a clinical hold on the IGNITE trial after a patient experienced decreased platelet counts, evidence of complement activation and reduced blood cell counts." (8/16/2019)
  • 2. According to Zacks Investment Research, "Solid Biosciences LLC is a life science company. It focuses on developing therapies for Duchenne muscular dystrophy. The company is engaged in developing gene therapies, disease modifying therapies and assistive devices, all targeting the various facets of the DMD. Its product candidate includes SGT-001, a gene transfer candidate which is in Phase I/II clinical trial to restore functional dystrophin protein expression in patients' muscles. Solid Biosciences LLC is headquartered in Cambridge, Massachusetts. " (7/17/2019)

Has Solid Biosciences been receiving favorable news coverage?

Media stories about SLDB stock have been trending negative on Monday, according to InfoTrie Sentiment. The research firm identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Solid Biosciences earned a coverage optimism score of -2.3 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Solid Biosciences.

Are investors shorting Solid Biosciences?

Solid Biosciences saw a increase in short interest during the month of July. As of July 31st, there was short interest totalling 4,247,000 shares, an increase of 16.7% from the June 30th total of 3,638,000 shares. Based on an average daily volume of 502,700 shares, the short-interest ratio is currently 8.4 days. Currently, 19.5% of the shares of the company are short sold. View Solid Biosciences' Current Options Chain.

Who are some of Solid Biosciences' key competitors?

What other stocks do shareholders of Solid Biosciences own?

Who are Solid Biosciences' key executives?

Solid Biosciences' management team includes the folowing people:
  • Dr. Andrey Juan Zarur, Co-Founder & Chairman of Directors (Age 48)
  • Mr. Ilan Ganot, Co-founder, Pres, CEO & Director (Age 45)
  • Mr. Pedro Alvaro Amorrortu, Chief Operating Officer (Age 47)
  • Dr. Carl Ashley Morris, Chief Scientific Officer (Age 49)
  • Dr. Andrey Zarur Ph.D., Co-Founder & Chairman of Directors (Age 48)

When did Solid Biosciences IPO?

(SLDB) raised $130 million in an IPO on Friday, January 26th 2018. The company issued 7,000,000 shares at a price of $18.00-$19.00 per share. J.P. Morgan, Goldman Sachs and Leerink Partners acted as the underwriters for the IPO and Nomura and Chardan were co-managers.

Who are Solid Biosciences' major shareholders?

Solid Biosciences' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (3.75%), Vanguard Group Inc. (2.35%), EcoR1 Capital LLC (2.34%), Northern Trust Corp (0.48%), Renaissance Technologies LLC (0.42%) and JPMorgan Chase & Co. (0.31%). Company insiders that own Solid Biosciences stock include Boxer Capital, Llc, Ilan Ganot, Joel Solomon Zev Schneider, Jorge Armando Quiroz, Juan Andrey Zarur, Life Sciences Maste Perceptive, Matthew Bennett Arnold and Pedro Alvaro Amorrortu. View Institutional Ownership Trends for Solid Biosciences.

Which institutional investors are selling Solid Biosciences stock?

SLDB stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley and JPMorgan Chase & Co.. Company insiders that have sold Solid Biosciences company stock in the last year include Boxer Capital, Llc, Ilan Ganot, Joel Solomon Zev Schneider, Jorge Armando Quiroz, Juan Andrey Zarur, Matthew Bennett Arnold and Pedro Alvaro Amorrortu. View Insider Buying and Selling for Solid Biosciences.

Which institutional investors are buying Solid Biosciences stock?

SLDB stock was purchased by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, BlackRock Inc., Vanguard Group Inc., Renaissance Technologies LLC, AQR Capital Management LLC, Walleye Trading LLC, Walleye Trading Advisors LLC and Charles Schwab Investment Management Inc.. View Insider Buying and Selling for Solid Biosciences.

How do I buy shares of Solid Biosciences?

Shares of SLDB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Solid Biosciences' stock price today?

One share of SLDB stock can currently be purchased for approximately $8.81.

How big of a company is Solid Biosciences?

Solid Biosciences has a market capitalization of $311.96 million. The company earns $-74,800,000.00 in net income (profit) each year or ($2.25) on an earnings per share basis. Solid Biosciences employs 111 workers across the globe.View Additional Information About Solid Biosciences.

What is Solid Biosciences' official website?

The official website for Solid Biosciences is http://www.solidbio.com/.

How can I contact Solid Biosciences?

Solid Biosciences' mailing address is 141 PORTLAND STREET FIFTH FLOOR, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-337-4680.


MarketBeat Community Rating for Solid Biosciences (NASDAQ SLDB)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  162 (Vote Outperform)
Underperform Votes:  147 (Vote Underperform)
Total Votes:  309
MarketBeat's community ratings are surveys of what our community members think about Solid Biosciences and other stocks. Vote "Outperform" if you believe SLDB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SLDB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel